You are here

Article Text

Article menu
Download PDFPDF
Letter
Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease
  1. S Aoki1,
  2. H Mizote1,
  3. A Minamoto1,
  4. M Suzuki1,
  5. H K Mishima1,
  6. H Tanaka2
  1. 1Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
  2. 2Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
  1. Correspondence to: A Minamoto Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan; aminahiroshima-u.ac.jp

https://doi.org/10.1136/bjo.2004.051391

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dry eye is one of the major symptoms of chronic graft versus host disease (CGVHD).1,2 Although effective therapy for dry eye associated with CGVHD has not been well established, successful treatment with systemic FK506,3,4 topical retinoic acid,5 topical cyclosporin A,6 and topical autologous serum have been reported.7,8 However, improved tear secretion was reported only in one patient with systemic FK506 by Masaoka et al,3 with limited description of ocular findings. We present a patient with dry eye associated with CGVHD, where systemic administration of FK506 resulted in improved ocular surface findings along with the Schirmer test value.

    CASE REPORT

    A 33 year old man had HLA matched sibling allogeneic peripheral blood stem cell transplantation in December 2000 for acute myeloid leukaemia in remission. He received cyclosporine A as GVHD prophylaxis, but it was …

    View Full Text